Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.60 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | LY96 | Q9Y6Y9 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18538450 | 0.87 | HDAC8 (0.63) | HDAC8MAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL18538453 | 0.84 | HDAC8 (0.84) | HDAC8LY96 | |
| SCHEMBL22867612 | 0.84 | MAOB (0.57) | FDPSMAOBMAPTMEN1ALDH1A1 | |
| SCHEMBL29581080 | 0.84 | MAOB (0.57) | FDPSMAOBMAPTMEN1ALDH1A1 | |
| SCHEMBL25288435 | 0.83 | HDAC8 (0.58) | HDAC8FDPSMAOBMAPTMEN1 | |
| SCHEMBL7205018 | 0.83 | HDAC8 (0.58) | HDAC8FDPSMAOBMAPTMEN1 | |
| SCHEMBL4592398 | 0.80 | MAPT (0.68) | MAOBMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL4592405 | 0.80 | MAPT (0.68) | MAOBMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL15248918 | 0.76 | HDAC8 (0.60) | HDAC8MEN1KMT2ALMNA | |
| SCHEMBL18538460 | 0.76 | HDAC8 (0.79) | HDAC8MAPTMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050922-A2 | HDAC8 INHIBITORS FOR TREATING CANCER | CITY OF HOPE | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050922-A2 | HDAC8 INHIBITORS FOR TREATING CANCER | HDAC8, HDAC1, HDAC7 | HDAC8 1/4885FDPS 4453/4885MAOB 4158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.